Cerevel Therapeutics Holdings, Inc.
CERE
株式のランク
#2812
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
株価
$44.96
最終同期: 2024-08-01
時価総額
$6.67B
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Cerevel Therapeutics Holdings, Inc. (CERE)
カテゴリー
Healthcare
Cerevel Therapeutics Holdings, Inc.（CERE）の利益
Mar 2024 時点の利益 TTM: $-459.91M
Cerevel Therapeutics Holdings, Inc. の最新の財務報告によると、同社の現在の利益は $-459.91M です。2022 年には $-351.35M の利益を上げ、これは 2021 年の利益 $-225.33M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Cerevel Therapeutics Holdings, Inc. の利益の推移（2012 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-459.91M | 6.38% |
| 2023 | $-432.34M | 23.05% |
| 2022 | $-351.35M | 55.92% |
| 2021 | $-225.33M | 48.08% |
| 2020 | $-152.17M | 18.56% |
| 2019 | $-128.34M | -72.32% |
| 2018 | $-463.64M | 1,546.73% |
| 2015 | $-28.16M | -3.97% |
| 2014 | $-29.32M | -9.81% |
| 2013 | $-32.51M | 10.55% |
| 2012 | $-29.41M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -1,246.94% |
US
|
|
| $-3.09B | 571.22% |
US
|
|
| $-4.02B | 773.25% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -524.14% |
NL
|
